A Phase 3 interventional study of REGN5713 and REGN5715 in Allergic Conjunctivitis, sponsored by Regeneron Pharmaceuticals. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Conjunctivitis, Allergic with a site in Canada — 2 open to participants now, 2 under way, none of them phase 3. Conjunctivitis, Allergic · Canada.
Among the 14 studies in Conjunctivitis, Allergic with a site in Canada, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 6 in phase 3, and was the 12th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →2 of the 14 studies in Conjunctivitis, Allergic with a site in Canada are open now. Recruiting first, the newest first:
Dr. Anne Ellis · Sites in Canada
Ages 18–70 · Healthy volunteers
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 6 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 98 across the 12 interventional studies, 156 across the 2 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 9 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 6 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Conjunctivitis, Allergic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug") to reduce eye allergy signs and symptoms due to birch tree pollen allergy.
The aim of the study is to see how safe and effective the study drug is at lowering allergic eye signs and symptoms compared with placebo. A placebo looks like a treatment but does not contain any real medicine.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria apply.
Participants will be randomized 1:1
Drug: REGN5713 · Drug: REGN5715
Participants will be randomized 1:1
Drug: Placebo
Ocular itch score in response to birch allergen challenge
Assessed using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale, a 0-4 point scale where 0 = none and 4= incapacitating itch, 0.5 unit increments
Time frame: At Day 8 post-Conjunctival Allergen Challenge (CAC)
Conjunctival redness score in response to birch allergen challenge
Assessed using the Ora Calibra® Hyperemia Scale (for conjunctival \[conjunctival redness scale\] ciliary \[ciliary redness scale\], episcleral \[episcleral redness scale\] vessel beds), a 0 to 4 point scale, where 0 = none and 4 = extremely severe, 0.5 unit increments
Time frame: At Day 8 post-CAC
Percent change in birch titrated Skin Prick Test (tSPT) in response to birch allergen challenge
Time frame: Baseline and at Day 8
Tearing score in response to birch allergen challenge
Assessed using the Ora Calibra® Conjunctival Allergen Challenge Tearing Scale, a 0-4 scale where 0 = none and 4 = very severe, 1 unit increments
Time frame: At Day 8 post-CAC
Total ocular symptom score (TOSS) in response to birch allergen challenge
TOSS is a summed score of ocular itch score (graded 0 = none to 4 = incapacitating itch), conjunctival redness score (graded 0 = none to 4 = extremely severe), and tearing score (graded 0 = none to 4 = very severe) for a total range from 0 to 12, where higher scores indicate worse responses.
Time frame: At Day 8 post-CAC
Total redness score in response to birch allergen challenge
The total redness score is calculated for CAC: range 0 to 12, where higher scores indicate worse responses (calculated as a sum of the bilateral averages for conjunctival redness score, graded 0 = none to 4 = extremely severe + ciliary redness score, graded 0 = none and 4 = extremely severe + episcleral redness score, graded 0 = none and 4 = extremely severe)
Time frame: At Day 8 post-CAC
Ciliary redness score in response to birch allergen challenge
Assessed using the Ora Calibra® Hyperemia Scale (for conjunctival \[conjunctival redness scale\] ciliary \[ciliary redness scale\], episcleral \[episcleral redness scale\] vessel beds), a 0 to 4 point scale, where 0 = none and 4 = extremely severe, 0.5 unit increments
Time frame: At Day 8 post-CAC
Episcleral redness score
Assessed using the Ora Calibra® Hyperemia Scale (for conjunctival \[conjunctival redness scale\] ciliary \[ciliary redness scale\], episcleral \[episcleral redness scale\] vessel beds), a 0 to 4 point scale, where 0 = none and 4 = extremely severe, 0.5 unit increments
Time frame: At Day 8 post-CAC
Change in birch tSPT
AUC of the mean wheal diameters
Time frame: Baseline and Day 8
Change in birch tSPT
AUC of the mean wheal diameters
Time frame: Baseline and Day 113
Percent change in birch tSPT
AUC of the mean wheal diameters
Time frame: Baseline and Day 113
Change in oak tSPT
AUC of the mean wheal diameter
Time frame: Baseline and Day 8
Percent change in oak tSPT
AUC of the mean wheal diameters
Time frame: Baseline and Day 8
Incidence of Treatment-emergent adverse event (TEAEs)
Time frame: Up to Day 113
Incidence of serious TEAEs
Time frame: Up to Day 113
Incidence of Adverse Events of Special Interest (AESIs)
Time frame: Up to Day 113
Total REGN5713 concentrations in serum over time
Time frame: Up to Day 113
Total REGN5715 concentrations in serum over time
Time frame: Up to Day 113
Incidence of Anti-drug antibody (ADAs) to REGN5713
Time frame: Up to Day 113
Titers of ADAs to REGN5713
Time frame: Up to Day 113
Incidence of ADAs to REGN5715
Time frame: Up to Day 113
Titers of ADAs to REGN5715
Time frame: Up to Day 113
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Apr 2025, 5 months.
Of 21 phase 3 interventional studies under Conjunctivitis, Allergic, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bremzalerbart